secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gain Therapeutics, Inc. (GANX)
CIK:        0001819411
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001558370-25-007744
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gain Therapeutics Q1 net loss $0.16/share; Phase 1b of GT-02287 enrollment underway
--------------------------------------------------------------------------------

- Net loss per share $0.16 (basic/diluted) vs $0.22 prior year; cash $9.1M as of March 31, 2025.
- R&D expenses $2.3M (down $0.2M), G&A expenses $2.1M (up $0.2M) compared to Q1 2024.
- Phase 1b study of GT-02287 for Parkinson's disease initiated; first biomarker analysis expected mid-2025.
- Gene Mack appointed CEO effective Jan 6, 2025; Gianluca Fuggetta assumed SVP Finance and PFO role.
- IND submission to FDA expected by year end 2025; Phase 1b completion expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/0001558370-25-007744-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819411/000155837025007744/ganx-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007744

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer